Who We Are

About Us

Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology - TGF-B signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.

Our lead compound, ISTH0036,  entered Phase 2a clinical development in Ophthalmology. In addition, Isarna has established a portfolio of antisense compounds addressing three important isoforms of TGF-β to treat fibrotic liver disease, such as NASH, and various forms of cancer.


Our Team

Join Our Team

If you want to join a pioneering company developing life-changing medication, please contact us.

News & Events

Find out more about Isarna and be up-to-date with our News, Events & Press Releases.